The announcement of a 5-year exclusive in-license agreement with Venture Life Group for Gelclair is a significant positive development for Jaguar Health, indicating potential future revenue growth and market expansion. This type of partnership news typically results in a positive short-term impact on a company's stock price due to increased investor confidence and anticipated growth.